Your new post is loading...
DIAXONHIT (Alternext : ALEHT, FR0004054427), a French leader in specialty in-vitro diagnostics for transplantation, infectious diseases and cancer, announces on behalf of its affiliate, InGen, the renewal of the exclusive commercial partnership for the commercialization in France of diagnostic tests for transplantation developed by One Lambda, Inc.
Read more: http://www.nasdaq.com/press-release/diaxonhit-renewal-of-commercial-partnership-with-one-lambda-inc-for-diagnostic-tests-in-20141112-00049#ixzz3JKBfOzaK ;
Today, DIAXONHIT'sInGen is the largest provider of diagnostic products to laboratories that are responsible for carrying out all tests related to transplantation in France. With a strong position in this sector, InGen has grown its total sales by 11% in the field of transplantation during 2013 .
"The renewal of this exclusive partnership demonstrates the quality of our sales team and the confidence of One Lambda in our marketing abilities. It enables our Group to strengthen its investment strategy over the long term in all areas of transplantation in order to further develop this critical market" says Dr. Loïc Maurel, President of the Management Board of Diaxonhit.
One Lambda develops and distributes several lines of HLA[1] typing tests utilizing both serological and molecular technologies. It manufactures a comprehensive line of antibody detection products that have been designed to monitor transplant patients, both pre- and post-transplant.